The Times Australia
The Times World News

.

New COVID vaccines may be coming to Australia. Here’s what to know about the JN.1 shots

  • Written by Paul Griffin, Professor, Infectious Diseases and Microbiology, The University of Queensland

COVID vaccines have unquestionably made a huge difference during this pandemic. For example, it’s estimated COVID shots[1] have saved more than 1.4 million lives in the World Health Organization’s (WHO) European region alone since their introduction in December 2020.

Unfortunately, SARS-CoV-2 (the virus that causes COVID) has continued to change quite quickly, and this affects how well immunity generated from both vaccination and past infection protects us. This issue is often referred to as “immune evasion[2]”.

One strategy to address this has been to update our vaccines, and we’ve done this four times already in Australia. Now, the Therapeutic Goods Administration (TGA) is considering what would be the fifth iteration of a COVID vaccine – a shot targeting the JN.1 omicron subvariant[3].

Here’s what you need to know about these updated boosters.

Keeping up with the COVID variants

Our initial vaccines targeted the original strain of SARS-CoV-2. The first update[4] still included the original strain[5] but added an early omicron subvariant BA.1. We then changed BA.1 to BA.4/5[6] with the original strain[7].

The most recent update[8] occurred in late 2023 when we reverted to having just one component[9] in the vaccine, in this case the omicron subvariant XBB.1.5[10].

The virus has continued to change. Another subvariant of omicron, JN.1, was first detected in August 2023[11] and went on to drive a significant wave of infections in Australia over summer.

JN.1 subsequently gave away to other subvariants you may know as the “FLiRT[12]” and “FLuQE[13]” variants which have seen a relatively large increase[14] in COVID activity over recent months. FLuQE, or KP.3, is currently dominant[15].

Although JN.1 is no longer driving many cases, given FLiRT and FLuQE are descended from JN.1, vaccines targeting JN.1 should do a good job[16] at protecting against these newer subvariants.

What’s the process?

As far back as April, the WHO recommended the use of vaccines targeting the JN.1 lineage[17] based on the expectation the virus would continue to evolve from JN.1. The European Medicines Agency[18] made the same recommendation.

Potentially from when it became clear that JN.1 was going to become dominant, but certainly from this point, pharmaceutical companies would have started working on tweaking their vaccines accordingly.

When these vaccines are ready and have been tested, they apply to the relevant regulatory bodies for approval.

The United States Food and Drug Administration (FDA) has recently approved an emergency use authorisation[19] for a Novavax vaccine targeting JN.1.

Meanwhile, the regulator in the United Kingdom has approved the JN.1-specific Spikevax from Moderna[20] and Comirnaty from Pfizer[21].

In Australia, our process differs slightly and tends to take a little longer. The TGA’s website[22] indicates applications for two JN.1 vaccines are currently under evaluation (Spikevax and Comirnaty). We won’t know when they’re going to be approved until the decision has been made, but hopefully this is not too far away.

The US has also approved KP.2 vaccines

In June, the FDA advised vaccine manufacturers to update their COVID vaccines[23] to target JN.1. But subsequently it recommended it would be preferable for vaccines to target the KP.2 strain[24] instead (FLiRT).

Moderna and Pfizer said they would be able to develop vaccines targeted to KP.2 and the FDA has since granted emergency use authorisation[25] for these two companies’ KP.2 vaccines.

It seems likely the difference between a JN.1 booster and KP.2 booster will be minimal. Both should provide significantly updated protection against currently circulating subvariants compared with the XBB vaccines. So we shouldn’t feel as though we’re missing out by not having plans for KP.2 boosters in Australia at the moment.

Are the new vaccines safe and effective?

Before approving updated boosters, regulators carefully review data looking at immune responses generated by the new vaccines against the newer variants, compared to previous vaccines.

Based on data mostly generated by the vaccine manufacturers, the updated JN.1 vaccines appear to lead to substantially improved immune responses[26] against multiple related sublineages including KP.2 and KP.3, compared to the XBB vaccines.

These recent updates are not expected to change the well-established safety profile[27] of the COVID vaccines. But as always, the vaccines’ safety (as well as efficacy) will continue to be monitored[28] even after they’re approved and rolled out.

A nurse drawing up a vaccine.
COVID vaccines are constantly monitored for safety. Carlos Giusti/AP/AAP

What about Novavax?

The COVID vaccines from Pfizer and Moderna are mRNA vaccines. These work by giving our body instructions to make SARS-CoV-2 spike proteins (proteins on the surface of the virus which it uses to attach to our cells). Then when we encounter SARS-CoV-2, our immune system is ready to respond.

The Novavax shot[29] is an adjuvanted protein-based vaccine[30], which means the proteins are manufactured in a lab and a component called an adjuvant is added to improve the body’s immune response. Vaccines using this type of technology have been around for some time so it’s considered a more traditional way of making a vaccine.

While our mRNA options work well, there are some people who can’t have[31] or don’t want an mRNA vaccine, so Novavax provides an important alternative option[32].

However, the updated Novavax booster does not yet seem to have an application before the TGA, so is likely to be some time away for us in Australia.

Some challenges remain

While it’s great we have been able to update our vaccines successfully, it would be ideal if we could develop vaccines that don’t need to be updated as often.

But perhaps the biggest determinant of how well a vaccine works is its uptake, and at the moment the uptake of COVID boosters is well below where it needs to be.

For example, as of August, only 31.8% of people[33] aged 75 and older had received a COVID vaccine in the previous six months (it’s recommended every six months[34] in this age group).

We also need to look at ways to approve updated COVID vaccines more quickly[35] and efficiently in this country, including non-mRNA options.

References

  1. ^ COVID shots (www.who.int)
  2. ^ immune evasion (www.nature.com)
  3. ^ JN.1 omicron subvariant (www.abc.net.au)
  4. ^ first update (www.tga.gov.au)
  5. ^ the original strain (www.tga.gov.au)
  6. ^ changed BA.1 to BA.4/5 (www.tga.gov.au)
  7. ^ the original strain (www.tga.gov.au)
  8. ^ most recent update (www.guild.org.au)
  9. ^ just one component (www.tga.gov.au)
  10. ^ omicron subvariant XBB.1.5 (www.tga.gov.au)
  11. ^ first detected in August 2023 (theconversation.com)
  12. ^ FLiRT (www.sbs.com.au)
  13. ^ FLuQE (theconversation.com)
  14. ^ a relatively large increase (www.health.gov.au)
  15. ^ currently dominant (www.health.nsw.gov.au)
  16. ^ a good job (www.sbs.com.au)
  17. ^ the JN.1 lineage (www.who.int)
  18. ^ European Medicines Agency (www.ema.europa.eu)
  19. ^ emergency use authorisation (www.nbcnews.com)
  20. ^ Spikevax from Moderna (www.gov.uk)
  21. ^ Comirnaty from Pfizer (www.gov.uk)
  22. ^ TGA’s website (www.tga.gov.au)
  23. ^ update their COVID vaccines (www.fda.gov)
  24. ^ to target the KP.2 strain (www.fda.gov)
  25. ^ emergency use authorisation (www.fda.gov)
  26. ^ improved immune responses (www.fda.gov)
  27. ^ safety profile (ausvaxsafety.org.au)
  28. ^ continue to be monitored (ausvaxsafety.org.au)
  29. ^ Novavax shot (www.forbes.com)
  30. ^ adjuvanted protein-based vaccine (ir.novavax.com)
  31. ^ can’t have (immunisationhandbook.health.gov.au)
  32. ^ alternative option (www.yalemedicine.org)
  33. ^ 31.8% of people (www.health.gov.au)
  34. ^ every six months (www.health.gov.au)
  35. ^ more quickly (www.sbs.com.au)

Read more https://theconversation.com/new-covid-vaccines-may-be-coming-to-australia-heres-what-to-know-about-the-jn-1-shots-237652

Times Magazine

Building an AI-First Culture in Your Company

AI isn't just something to think about anymore - it's becoming part of how we live and work, whether we like it or not. At the office, it definitely helps us move faster. But here's the thing: just using tools like ChatGPT or plugging AI into your wo...

Data Management Isn't Just About Tech—Here’s Why It’s a Human Problem Too

Photo by Kevin Kuby Manuel O. Diaz Jr.We live in a world drowning in data. Every click, swipe, medical scan, and financial transaction generates information, so much that managing it all has become one of the biggest challenges of our digital age. Bu...

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Decline of Hyper-Casual: How Mid-Core Mobile Games Took Over in 2025

In recent years, the mobile gaming landscape has undergone a significant transformation, with mid-core mobile games emerging as the dominant force in app stores by 2025. This shift is underpinned by changing user habits and evolving monetization tr...

Understanding ITIL 4 and PRINCE2 Project Management Synergy

Key Highlights ITIL 4 focuses on IT service management, emphasising continual improvement and value creation through modern digital transformation approaches. PRINCE2 project management supports systematic planning and execution of projects wit...

What AI Adoption Means for the Future of Workplace Risk Management

Image by freepik As industrial operations become more complex and fast-paced, the risks faced by workers and employers alike continue to grow. Traditional safety models—reliant on manual oversight, reactive investigations, and standardised checklist...

The Times Features

Why Diversification Still Matters in a Volatile Economy

Market volatility, geopolitical conflicts, inflation fears—these are only some of the wild cards that render the current financial environment a tightrope to walk. Amidst all thi...

Specialised nutrition gains momentum in supporting those living with early Alzheimer's disease

With high public interest in Alzheimer’s disease, there is growing awareness of the important role nutrition plays in supporting memory and cognitive function in people diagnosed...

From clinics to comfort: how sleep retreats are redefining care in Australia

Australia is amid a sleep health crisis. Nearly 40% of adults report inadequate sleep, and the consequences are far-reaching, impacting everything from cardiovascular health to...

Is our mental health determined by where we live – or is it the other way round? New research sheds more light

Ever felt like where you live is having an impact on your mental health? Turns out, you’re not imagining things. Our new analysis[1] of eight years of data from the New Zeal...

Going Off the Beaten Path? Here's How to Power Up Without the Grid

There’s something incredibly freeing about heading off the beaten path. No traffic, no crowded campsites, no glowing screens in every direction — just you, the landscape, and the...

West HQ is bringing in a season of culinary celebration this July

Western Sydney’s leading entertainment and lifestyle precinct is bringing the fire this July and not just in the kitchen. From $29 lobster feasts and award-winning Asian banque...